z-logo
open-access-imgOpen Access
Gadolinium-chelate functionalized magnetic CuFeSe2 ternary nanocrystals for T1-T2 dual MRI and CT imaging in vitro and in vivo
Author(s) -
Lu-Yao Lai,
Ying Jiang,
Guang-Ping Su,
Min Wu,
Xiaofei Lü,
Shaozhi Fu,
Lu Yang,
Jiwu Shu
Publication year - 2021
Publication title -
materials research express
Language(s) - English
Resource type - Journals
ISSN - 2053-1591
DOI - 10.1088/2053-1591/abf1a2
Subject(s) - materials science , magnetic resonance imaging , gadolinium , in vivo , nuclear magnetic resonance , preclinical imaging , mri contrast agent , biomedical engineering , medicine , radiology , physics , microbiology and biotechnology , biology , metallurgy
CuFeSe 2 nanomaterial with high thermal conversion efficiency, well superparamagnetism, effective x-ray attenuation ability, multifunctional groups and excellent biocompatibility is beneficial to the construction of multimodal imaging probes which can combine various imaging modes to provide a synergistic advantage over a single imaging mode. This study aimed to develop a novel multimodal nanocontrast agent CuFeSe 2 @diethylenetriaminepentaacetic acid (DTPA)-Gd to obtain imaging information with high specificity, high sensitivity and high contrast. The morphology and physical characteristics of CuFeSe 2 @DTPA-Gd were detected by transmission electron microscope, scanning electron microscope, x-ray single crystal diffraction, vibrating sample magnetometer and fourier transform infrared spectrometer. The toxicity of CuFeSe 2 @DTPA-Gd in vivo was evaluated by hematoxylin-eosin staining. The imaging capability of CuFeSe 2 @DTPA-Gd in vitro and in vivo was evaluated by magnetic resonance imaging (MRI) and computed tomography (CT). This study successfully prepared nanoparticles CuFeSe 2 @DTPA-Gd, and experimental results in this study demonstrated CuFeSe 2 @DTPA-Gd is expected to be a useful CT and MRI T1-weighted imaging/T2-weighted imaging three-modal contrast agent in clinic.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here